Assessment of Novel Proteins Triggering Celiac Disease via Docking-Based Approach

Molecules. 2023 Dec 26;29(1):138. doi: 10.3390/molecules29010138.

Abstract

Human leukocyte antigens (HLAs) are pivotal in antigen processing, presenting to CD4+ T cells, and are linked to autoimmune disease susceptibility. In celiac disease, HLA-DQ2.5 and HLA-DQ8.1 bind gluten peptides on APCs, some recognized by CD4+ T cells, prompting inflammation and tissue damage. While extensively studied experimentally, these alleles lack comprehensive in silico analysis. To explore peptide-HLA preferences, we used molecular docking on peptide libraries, deriving quantitative matrices (QMs) for evaluating amino acids at nine-residue peptide binding cores. Our findings tie specific residue preferences to peptide backbone conformations. Validating QMs on known binders and non-binders showed strong predictive power (89-94% accuracy). These QMs excel in screening protein libraries, even whole proteomes, notably reducing time and costs for celiac disease risk assessment in novel proteins. This computational approach aligns with European Food Safety Authority guidance, promising efficient screening for potential celiac disease triggers.

Keywords: HLA-DQ2.5; HLA-DQ8.1; celiac disease; molecular docking; peptide binding prediction; quantitative matrix.

MeSH terms

  • Amino Acids
  • Celiac Disease*
  • Glutens
  • Humans
  • Molecular Docking Simulation
  • Peptides

Substances

  • Glutens
  • Amino Acids
  • Peptides